KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings: 2009-2024

Historic Retained Earnings for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$7.3 billion.

  • Alnylam Pharmaceuticals' Retained Earnings rose 0.60% to -$7.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 billion, marking a year-over-year increase of 0.60%. This contributed to the annual value of -$7.3 billion for FY2024, which is 3.97% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Retained Earnings stood at -$7.3 billion for FY2024, which was down 3.97% from -$7.0 billion recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Retained Earnings ranged from a high of -$4.6 billion in FY2020 and a low of -$7.3 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$7.0 billion (2023), whereas its average is -$7.0 billion.
  • Data for Alnylam Pharmaceuticals' Retained Earnings shows a maximum YoY dropped of 23.03% (in 2020) over the last 5 years.
  • Alnylam Pharmaceuticals' Retained Earnings (Yearly) stood at -$4.6 billion in 2020, then declined by 18.60% to -$5.4 billion in 2021, then dropped by 20.80% to -$6.6 billion in 2022, then dropped by 6.70% to -$7.0 billion in 2023, then decreased by 3.97% to -$7.3 billion in 2024.